Table 1.
Subject characteristics.
| ADNI | CN-Aβ− (n = 28) | CN-Aβ+ (n = 32) | MCI- Aβ+ (n = 21) | p-value | |
|---|---|---|---|---|---|
| Age | 74.07 (6.82) | 76.88 (5.86) | 74.86 (7.57) | 0.251 | |
| Sex (m/f) | 12/16 | 12/20 | 11/10 | 0.564 | |
| Education (M/SD) | 16.8 (1.94) | 15.0 (4.56) | 15.62 (2.92) | 0.214 | |
| MMSE (M/SD) | 29.25 (1.02)c | 28.5 (2.13)c | 26.53 (4.03)a,b | 0.010 | |
| ADAS-global (M/SD) | 7.93 (4.27)c | 12.42 (7.16)c | 17.61 (10.38)a,b | 0.001 | |
| ApoE ε4 status (pos/neg) | 5/23 | 19/13 | 14/7 | 0.002 | |
| Global AV45 SUVR(M/SD) | 1.04 (0.04)b,c | 1.33 (0.21)a | 1.34 (0.13)a | <0.001 | |
| Mean tau-PET follow-up time in years (M/SD) | 1.30 (0.52) | 1.27 (0.46) | 1.37 (0.57) | 0.817 |
| BioFINDER | CN-Aβ− (n = 16) | CN-Aβ+ (n = 16) | MCI- Aβ+ (n = 7) | AD dementia (n = 18) | |
|---|---|---|---|---|---|
| Age | 73.88 (5.32) | 75.44 (6.09) | 72.71 (6.63) | 69.83 (10.48) | 0.192 |
| Sex (m/f) | 10/6 | 6/10 | 2/5 | 11/7 | 0.245 |
| Education (M/SD) | 12.59 (4.06) | 10.56 (3.22) | 11.14 (2.67) | 13.44 (3.26) | 0.097 |
| MMSE (M/SD) | 29 (1.1)d | 29.31 (1.08)d | 25.57 (2.94) | 22.06 (5.17)a,b | <0.001 |
| ADAS-delayed recall (M/SD) | 1.81 (1.47)c,d | 2.31 (1.49)c,d | 6.17 (2.4) | 7.62 (2.45)a,b | <0.001 |
| ApoE ε4 status (pos/neg) | 0/16 | 10/6 | 4/3 | 11/7 | <0.001 |
| Global Flutemetamol SUVR | 0.52 (0.03)b,c,d | 0.77 (0.12)a,d | 0.84 (0.14)a | 0.97 (0.15)a,b | <0.001 |
| Mean tau-PET follow-up time in years (M/SD) | 2.03 (0.47) | 1.91 (0.32) | 1.82 (0.12) | 1.97 (0.34) | 0.484 |
p-values were derived from ANOVA for continuous measures and from Chi-squared tests for categorical measures
M male, f female, MMSE Mini-Mental State Exam, ADAS Alzheimer’s disease assessment scale, cognitive subscale
Mean values significantly (p < 0.05) different from—
aCN-Aβ−
bCN-Aβ+
cMCI-Aβ+
dAD dementia